EECP Improves Glycemic Control in Patients With Type II Diabetes that Persist for Up to 3 Months following Treatment 體外反搏治療有助2型糖尿病患者控制 血糖 ;成效持續3個月

Source From 資料來源 : https://link.springer.com/article/10.1007/s00592-016-0866-9

EECP Improves Glycemic Control in Patients With Type II Diabetes that Persist for Up to 3 Months following Treatment

AIMS:

The purpose of the present study was to evaluate the potential clinical benefits of EECP on glycemic parameters [fasting plasma glucose (FPG), postprandial glucose (PPG120), glycosylated hemoglobin (HbA1c)] in patients with a clinical diagnosis of type II diabetes mellitus (T2DM).

METHODS:

Thirty subjects (60.7 ± 1.9 years) with T2DM were randomly assigned (2:1 ratio) to receive either 35 1-h sessions of EECP (n = 20) or time-matched control of standard care (n = 10). FPG, PPG120, and HbA1c were evaluated before and at 48 h, 2 weeks, 3 and 6 months following EECP treatment or time-matched control.

RESULTS:

EECP significantly decreased FPG (-14.6 and -12.0 %), PPG120 (-14.6 and -13.5 %), and HbA1c (-11.5 and -19.6 %) 48 h following EECP and 2 weeks following EECP, respectively. HbA1c remained significantly reduced at 3 months following EECP (-14.3 %). The homeostasis model assessment of insulin resistance (-31.1 %) and whole-body composite insulin sensitivity index (+54.2 %) were significantly improved 48 h following EECP. Nitrite/nitrate (NO x ) was significantly increased 48 h following EECP (+48.4 %) and 2 weeks (+51.9 %) following EECP treatment.

CONCLUSIONS:

Our findings provide novel evidence that EECP improves glycemic control in patients with T2DM that persist for up to 3 months following treatment.

「體外反搏治療有助2型糖尿病患者控制 血糖 ;成效持續3個月」

目的

本研究旨在評估體外反搏治療(EECP)對II型糖尿病(T2DM)患者的 血糖 參數[空腹血漿葡萄糖(FPG),餐後 血糖 (PPG120),糖化血紅蛋白(HbA1c)]的潛在臨床效益。

方法

選擇30名II型糖尿病患者,並以2:1比例隨機分配他們接受35次(每次1小時)的EECP治療或對照組的標準治療。我們分別在患者接受EECP治療或對照治療後的48小時、2週、3個月和6個月評估他們的FPG、PPG120和HbA1c。

結果

在接受EECP治療後48小時和2週,患者的FPG分別減少了14.6%和12.0%,PPG120分別減少了14.6%和13.5%,HbA1c分別減少了11.5%和19.6%。在接受EECP治療後的3個月,HbA1c仍顯著降低(14.3%)。EECP治療後48小時,胰島素抵抗的體內平衡模型評估(-31.1%)和全身綜合胰島素敏感性指數(+54.2%)顯著改善。在EECP治療後的48小時和2週,亞硝酸/硝酸鹽(NOx)顯著增加(分別增加了48.4%和51.9%)。

結論

我們的研究結果提供了新的證據,表明EECP治療可以改善II型糖尿病患者的 血糖 控制,在治療後長達3個月的時間內持續有效。

×